Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 6, 2000, Pages 545-549

  Li, Ming ^a   Lotan, Reuben ^a   Levin, Bernard ^a   Tahara, Eiichi ^b   Lippman, Scott M ^a   Xu, Xiao Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; DRUG EFFECT; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ACTINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASPIRIN; BLOTTING, WESTERN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ELECTROPHORESIS; ESOPHAGEAL NEOPLASMS; GENES, BCL-2; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0034130336     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. McCann, J. Esophageal cancers: changing character, increasing incidence. J. Natl. Cancer Inst., 91: 497-498, 1999.
3. Kim, R., Weissfeld, J. L., Reynolds, J. C., and Kuller, L. H. Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol. Biomark Prev., 6: 369-377, 1997.
4. Flood, W. A., and Forastiere, A. A. Esophageal cancer. Curr. Opin. Oncol., 7: 381-386, 1995.
5. Roth, J. A., Putnam, J. B., Rich, T. A., and Forastiere, A. A. Cancer of the esophagus. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 980-1020. Philadelphia: Lippincott-Raven Publishers, 1997.
6. Ilson, D. H., and Kelsen, D. P. Combined modality therapy in the treatment of esophageal cancer. Semin. Oncol., 21: 493-507, 1994.
7. Blot, W. Esophageal cancer trends and risk factors. Semin. Oncol., 21: 403-410, 1994.
8. Lerut, T. Oesophageal carcinoma: past and present studies. Eur. J. Surg. Oncol., 22: 317-323, 1996.
9. Kok, T. C., and Timanus, H. W. Neoadjuvant treatment in oesophageal cancer: the needs for future trials. Eur. J. Surg. Oncol., 22: 323-325, 1996.
10. Becker, H. D. Esophageal cancer, early disease: diagnosis and current treatment. World J. Surg., 18: 331-338, 1994.
11. Lee, I. M., Hennekens, C. H., and Buring, J. E. Use of aspirin and other nonsteroidal anti-inflammatory drugs and the risk of cancer development. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 599-607. Philadelphia: Lippincott-Raven Publishers, 1997.
12. Farrow, D. C., Vaughan, T. L., Hansten, P. D., Stanford, J. L., Risch, H. A., Gammon, M. D., Chow, W. H., Dubrow, R., Ahsan, H., Mayne, S. T., Schoenberg, J. B., West, A. B., Rotterdam, H., Fraumeni, J. F., Jr., and Blot, W. J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomark. Prev., 7: 97-102, 1998.
13. Funkhouser, E. M., and Sharp, G. B. Aspirin and reduced risk of esophageal carcinoma. Cancer (Phila.), 76: 1116-1119, 1995.
14. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis. J. Natl. Cancer Inst., 90: 1529-1536 (Part I), 1609-1620 (Part II), 1998.
15. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.
16. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459, 1997.
17. Elder, D. J. E., Halton, D. E., Hague, A., and Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-intlammatory drug: independence from COX-2 protein expression. Clin. Cancer Res., 3: 1679-1683, 1997.
18. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., Beauchamp, R. D., and DuBois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest., 99: 2254-2259, 1997.
19. Zhu, G. H., Wong, B. C., Eggo, M. C., Ching, C. K., Yuen, S. T., Chan, E. Y., Lai, K. C., and Lam, S. K. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc. Br. J. Cancer, 79: 393-400, 1999.
20. Aas, A. T., Tonnessen, T. I., Brun, A., and Salford, L. G. Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. J. Neurooncol., 24: 171-180, 1995.
21. Zhang, F., Subbaramaiah, K., Altorki, N., and Dannenberg, A. J. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J. Biol. Chem., 273: 2424-2428, 1998.
22. 2 in human colon cancer cells. Cancer Res., 58: 362-366, 1998.
23. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
24. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.
25. Dong, Z., Huang, C., Brown, R. E., and Ma, W. Y. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J. Biol. Chem., 272: 9962-9970, 1997.
26. Kopp, E., and Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science (Washington DC), 265: 956-959, 1994.
27. Zimmermann, K. C., Sarbia, M., Weber, A. A., Borchard, F., Gabbert, H. E., and Schror, K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 59: 198-204, 1999.
28. Wilson, K. T., Fu, S., Ramanujam, K. S., and Meltzer, S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res., 58: 2929-2934, 1998.
29. Balch, C. M., Dougherty, P. A., Cloud, G. A., and Tilden, A. B. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery (St. Louis), 95: 71-77, 1984.